PHARMACEUTICAL giant AstraZeneca has won Europe-wide approval for its diabetes drug Komboglyze.
The treatment, which was developed in a partnership with US peer Bristol-Myers Squibb, helps glycaemic control in adult patients with type two diabetes.
The approval comes following a study and series of tests involving 4,326 patients.
Type two diabetes accounts for approximately 90 to 95 per cent of all cases of diagnosed diabetes in adults. In Europe alone there are around 50m people suffering with the condition.